2. Academic Validation
  3. USP7: Novel Drug Target in Cancer Therapy

USP7: Novel Drug Target in Cancer Therapy

  • Front Pharmacol. 2019 Apr 30:10:427. doi: 10.3389/fphar.2019.00427.
Zhiru Wang 1 2 3,  Wenting Kang 1 2,  Yinghua You 1 2,  Jingru Pang 1 2,  Hongmei Ren 1 2,  Zhenhe Suo 3,  Hongmin Liu 1 2,  Yichao Zheng 1 2
Affiliations

Affiliations

  • 1 School of Pharmaceutical Sciences, Zhenghzou University, Zhengzhou, China.
  • 2 Collaborative Innovation Centre of New Drug Research and Safety Evaluation, Henan Province, and Key Laboratory of Advanced Drug Preparation Technologies, Zhengzhou University, and Key Laboratory of Henan Province for Drug Quality and Evaluation, Ministry of Education of China, Zhengzhou, China.
  • 3 Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
PMID: 31114498 DOI: 10.3389/fphar.2019.00427
Abstract

Ubiquitin specific protease 7 (USP7) is one of the deubiquitinating Enzymes (DUB) that erases ubiquitin and protects substrate protein from degradation. Full activity of USP7 requires the C-terminal Ub-like domains fold back onto the catalytic domain, allowing the remodeling of the active site to a catalytically competent state by the C-terminal peptide. Until now, numerous proteins have been identified as substrates of USP7, which play a key role in cell cycle, DNA repair, chromatin remodeling, and epigenetic regulation. Aberrant activation or overexpression of USP7 may promote oncogenesis and viral disease, making it a target for therapeutic intervention. Currently, several synthetic small molecules have been identified as inhibitors of USP7, and applied in the treatment of diverse diseases. Hence, USP7 may be a promising therapeutic target for the treatment of Cancer.

Keywords

DNA damage; USP7; deubiquitination; immune; structure.

Figures